Warning Letter, Form 483 Should Be Revisited By FDA Counsel, Pilot Suggests

The absence of an FDA commissioner affords Chief Counsel Daniel Troy a greater role in keeping the agency within its legal and regulatory bounds in conducting enforcement activity, panelists noted at a Washington Legal Foundation briefing Oct. 3.